Research
Hormonal
GLP-1 receptor agonists reduced major adverse cardiovascular events (MACE) by 31% in Asians.
GLP-1RAs may provide significant cardiovascular benefits for Asian populations.
StrongSupportsmedium confidence
GLP-1RAs reduced MACE by 31% in Asians.
Why this rating
Based on a meta-analysis of multiple trials.
Source
GLP-1 Receptor Agonists for Obesity in Asians: Evidence From East Asia and Research Gaps in South Asia
Ahmad Alam · Journal of Diabetology · 2025
DOI 10.4103/jod.jod_164_25
Meta-analysisCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →